Roddy E, Clarkson K, Blagojevic-Bucknall1 M, et al. - In a multicentre open-label randomized trial, 399 individuals with a gout flare enrolled Between January 29, 2014, and December 31, 2015, from 100 general practices were randomized evenly to naproxen 750 mg immediately then 250 mg every 8 hours for 7 days or low-dose colchicine 500 mcg three times per day for 4 days (naproxen n = 200, colchicine n = 199) in order to contrast the efficiency and safety of naproxen and low-dose colchicine for treating gout flares in primary care. No important between-group variation in average pain-change scores over days 1–7 was found. During days 1–7, diarrhea and headache were more prevalent in the colchicine group vs naproxen group except for constipation. In summary, between individuals with a gout flare randomized to either naproxen or low-dose colchicine, no variation in pain intensity over 7 days was discovered. Moreover, naproxen led to fewer side effects suggesting naproxen as first-line treatment in primary care in the absence of contraindications for gout flares.